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The Pediatric Assembly of the
American Thoracic Society assembled an
interdisciplinary panel to develop clinical
practice guidelines for the evaluation of
infants with recurrent or persistent
wheezing. This summary of the guideline
is intended for practicing clinicians.
Wheezing during infancy is common: a
longitudinal birth cohort study of healthy,
full-term infants found that 34% of these
children had at least one episode of
wheezing before age 3 years (1). Although
many of these children have mild, easily
treated wheezing, some progress to have
persistent wheezing that does not respond
to conventional therapies.
For the purposes of these guidelines,
infantile wheezing is defined as recurrent or
persistent episodes of wheezing in infants
younger than 24 months of age. The
guidelines address infantile wheezing that
is persistent despite treatment with
bronchodilators, inhaled corticosteroids,
or systemic corticosteroids.
Recommendation 1: For infants with
persistent wheezing despite treatment with
bronchodilators, inhaled corticosteroids,
or systemic corticosteroids, we
suggest airway survey via flexible
fiberoptic bronchoscopy (conditional
recommendation, very low quality of
evidence).
Ten case series that enrolled 1,364
children were identified. The case series
reported that 33% of children who
underwent airway survey for respiratory
symptoms were found to have an anatomic
abnormality known to cause wheezing. The
most common lesions were airway malacia
and compression by vascular structures.
Infants with airway malacia are
usually managed by observation alone,
because the vast majority improve over time.
Interventions such as positive pressure
ventilation, surgery, or stenting are reserved
for infants with life-threatening
complications, such as complete airway
obstruction, respiratory failure, recurrent
pneumonia, or failure to thrive.
Aortopexy is the most common
surgical intervention; it relieves airway
obstruction in nearly all patients with
tracheomalacia but is less effective in
patients with tracheobronchomalacia.
Airway stenting may also improve airway
obstruction, but the formation of
granulation tissue is a common and
problematic complication. Vascular
anomalies, such as vascular rings and
vascular slings, are unlikely to self-resolve;
therefore, surgical intervention is usually
performed in symptomatic patients.
In seven case series, improvement in
symptoms occurred in 88 to 100% of
patients, with complete resolution
achieved in 50% of patients.
Taken together, the evidence suggests
that approximately 30% of infants with
persistent wheezing who undergo a
bronchoscopic airway survey are likely to
benefit from the evaluation. Benefits include
identifying a lesion that may be surgically
corrected; avoiding the burden, costs, and
potential harms of further diagnostic testing;
reducing the use of ineffective medications;
reducing the frequency of physician visits;
and providing parental reassurance. These
benefits were judged by the guideline
committee to outweigh the burdens, cost,
and complications of flexible bronchoscopy.
Recommendation 2: For infants
with persistent wheezing despite
treatment with bronchodilators, inhaled
corticosteroids, or systemic corticosteroids,
we suggest bronchoalveolar lavage (BAL)
(conditional recommendation, very low
quality of evidence).
Twenty case series were evaluated and
found that, on average, 40 to 60% of infants
with recurrent wheezing had a positive BAL
culture. A randomized trial of children with
cough due to presumed bacterial bronchitis
found that 48% of children who received
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antibiotics had resolution of cough (3).
However, only 16% of those who did not
receive antibiotics had resolution of cough.
The results of these studies suggest
that 20 to 30% of infants with persistent
wheezing who undergo bronchoscopy with
BAL will be found to have a lower airway
infection that improves with appropriate
antibiotic therapy. Use of BALmay also help
minimize unnecessary antibiotic therapy
and its risks of side effects, including
rash and acquisition of resistance.
Recommendation 3: In infants
with persistent wheezing despite
treatment with bronchodilators,
inhaled corticosteroids, or systemic
corticosteroids, we recommend research
studies that compare clinical outcomes
among infants who are managed
according to infant pulmonary function
testing performed using the raised
volume rapid thoracoabdominal
compression (RVRTC) technique versus
those who are managed according to
clinical assessment alone.
Numerous studies have reported
pulmonary function tests in children with
wheezing, but most were in older children.
Of the limited number of studies in infants,
only two studies (from the same cohort
of patients at different points in time)
measured clinical outcomes after the
assessment of bronchodilator
responsiveness using the RVRTC
technique (4, 5). Both studies found that
bronchodilator responsiveness predicted
acute episodes of wheezing necessitating
treatment with systemic steroids. No
studies compared clinical outcomes after
management based on infant pulmonary
function tests versus management based
on clinical assessment alone.
The guideline committee decided
there was insufficient evidence to judge
the balance of benefits versus risks, burden,
and cost of managing infants with wheezing
according to the results of pulmonary
function testing performed using the
RVRTC technique. Benefits include raising
or lowering the index of suspicion for
various diseases such as interstitial lung
disease and anatomic abnormalities, as well
as guiding further diagnostic testing and
management. Risks include sedation,
gastric distension, aerophagia, and airway
occlusion; in addition, testing requires
significant resource utilization. The
guideline committee recommended
research studies to fill the knowledge gap.
Recommendation 4a: For infants
without eczema who have persistent
wheezing despite treatment with standard
therapies, we suggest NOT using
empiric food avoidance (conditional
recommendation, very low quality of
evidence).
Recommendation 4b: We
recommend research to determine
whether or not empiric food avoidance is
beneficial for the subgroup of infants
who are IgE-positive to food antigens.
In infants with persistent wheezing, but
without eczema, four studies investigated
the effect of empiric food avoidance on
wheezing frequency. Three of the studies
were randomized trials that assigned infants
to receive either regular formula (standard
diet) or a restricted diet (cow’s milk–free or
partially hydrolyzed formula) during the
first 4 months of life. None of the trials
found an effect on the incidence of
wheezing. The fourth study was a
prospective cohort study that evaluated
the introduction of commonly allergenic
foods before or after 6 months of age.
The study found no effect on wheezing.
No studies investigated the subgroup of
infants with positive IgE antigen testing to
food, nor were there any that evaluated
additional important outcomes such as
healthcare utilization, medication usage,
and parental distress.
Given that all studies to date have
found no effect on wheezing and that food
restriction is burdensome, the guideline
committee recommended against the
routine empiric avoidance of foods. The
committee, however, acknowledge that a
trial of food avoidance may be warranted in
some patients, such as those with a history of
respiratory symptoms triggered by food
exposure or IgE positivity to specific food
antigens. Additional research targeting such
patients was recommended.
Recommendation 5: For infants with
persistent wheezing that is not relieved by
bronchodilators, inhaled corticosteroids,
or systemic corticosteroids, we suggest
24-hour esophageal pH monitoring
(conditional recommendation, very low
quality of evidence).
No randomized trials were identified
comparing clinical outcomes among
patients who underwent 24-hour esophageal
pH monitoring to detect gastroesophageal
reflux. However, four small case series were
identified that used 24-hour esophageal pH
monitoring to diagnose reflux in wheezy
infants and children. One study identified
reflux in 76% of the children with asthma
studied. After 3 months of proton pump
inhibitor therapy, there was significant
improvement in respiratory symptoms,
bronchodilator and systemic steroid use,
and exacerbation and hospitalization
frequency (6). These results were similar to
the other three case series, which identified
gastroesophageal reflux in 47 to 100% of
infants and children with persistent wheeze
and found that more than 83% improved
with medical or surgical treatment.
The guideline committee decided that
24-hour esophageal pH monitoring with
treatment of those with confirmed
gastroesophageal reflux is preferable to an
empiric trial of anti-acid therapy. Testing is
generally well tolerated; in contrast, empiric
therapy may be inappropriate in up to one-
third of patients, creating unnecessary cost,
burden, and risk. Proton pump inhibitor
therapy has been associated with an
increased risk of pneumonia in older
children. Furthermore, children whose
reflux requires fundoplication are
unlikely to respond to empiric anti-acid
therapy, which may be misinterpreted
as a lack of evidence of gastroesophageal
reflux, and the patient therefore may never
be offered potentially curative surgical
therapy.
There was significant variability in
the way pH monitoring was performed,
including the threshold used to declare
studies abnormal. In addition, many
studies were performed without
impedance monitoring, which may have
underestimated the prevalence of
nonacid reflux.
Recommendation 6: For infants with
persistent wheezing that is not relieved by
bronchodilators, inhaled corticosteroids,
or systemic corticosteroids, we suggest
24-hour esophageal pH monitoring
rather than upper gastrointestinal series
(conditional recommendation, very low
quality evidence).
Three studies evaluating the accuracy
of upper gastrointestinal series for
identification of gastroesophageal reflux
in infants and children indicate that
upper gastrointestinal series have a
sensitivity of 68 to 79% and specificity
of 82% compared with esophageal pH
monitoring, which is considered the
reference standard.
The guideline committee did not
believe that the potential benefits of an
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upper gastrointestinal series (it is less
invasive, shorter, and hospitalization is
not required) outweigh the 21 to 32% risk
of a false-negative result (i.e., a test result
excluding gastroesophageal reflux in a
patient who actually has reflux), the likely
result of which is a missed or delayed
opportunity to treat. An upper
gastrointestinal series also requires radiation
exposure and patient cooperation.
Recommendation 7: For infants with
persistent wheezing that is not relieved by
bronchodilators, inhaled corticosteroids,
or systemic corticosteroids, we suggest
24-hour esophageal pH monitoring rather
than gastrointestinal scintigraphy
(conditional recommendation, very low
quality evidence).
In the only study comparing
scintigraphy to 24-hour esophageal pH
monitoring, scintigraphy had a sensitivity
and specificity of 15 and 73%, respectively (7).
The guideline committee did not
believe that the potential benefits of
gastroesophageal scintigraphy (less
invasive, shorter testing) outweigh the
85% risk of a false-negative result, the
likely result of which is a missed
or delayed opportunity to treat.
Scintigraphy also requires radiation
and is expensive.
Recommendation 8: For infants
without neurologic pathology with
persistent wheezing that is not relieved by
bronchodilators, inhaled corticosteroids,
or systemic corticosteroids, we suggest a
swallowing function study to evaluate for
aspiration (weak recommendation, very
low quality of evidence).
Two case series reported the prevalence
of swallowing dysfunction and clinical
outcomes among infants younger than
12 months of age with chronic respiratory
symptoms. The series found swallowing
dysfunction in 10 to 15% of patients who
had respiratory symptoms/vomiting. The
infants were treated with thickening of oral
or tube feeds (nasogastric, gastrostomy, or
nasojejunal feeds), which resulted in an
improvement in respiratory symptoms in
more than 90% of infants.
On the basis of this, the guideline
committee concluded that a swallowing
evaluation may lead to management that
reduces symptoms, medication usage,
further diagnostic testing, and health care
utilization, as well as providing parental
reassurance. These benefits were believed to
outweigh the drawbacks, which include
the cost, need for a speech pathologist,
need for patient cooperation, risk of




Given the prevalence of wheezing in infants,
there is an urgent need for large clinical
studies that address the safety, efficacy, and
cost effectiveness of the diagnostic tests
described in this guideline to be conducted
to inform clinical decisions in this
vulnerable population.
For qualifying remarks related to the
summary above, see the full clinical practice
guideline (2). n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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